Page 17 - Commons Project News Today : Breaking News, Live Updates & Top Stories | Vimarsana

With widespread overseas travel unlikely until at least 2022, could we be on the brink of a document that’ll make international jaunts come back sooner?

They are being spruiked as the post-pandemic ticket to travel freedom. A ‘passport’ of sorts which will play as a crucial key for cities and countries reliant on tourism dollars to revive struggling economies. Dubbed the ‘vaccine pass’ or ‘vaccine passport’, these documents – which are going to be trialled by Air New Zealand from April on flights between Auckland and Sydney – would essentially be a digital document than ensures tourists are virus-free when border lockdowns lift and travelling resumes. The trial of the Travel Pass app, developed by the I...

The coronavirus pandemic is still extremely serious. Families are grieving: more than 108,000 people have died from Covid-19 in the UK. The virus spread rapidly across the world and into the UK by air travel. And the UK lockdown means holidays at home or abroad are currently illegal. But many people are looking ahead to later in 2021 and the opportunities for future holidays. With the UK well ahead of other major European nations in its...

Immunotourism: How Covid vaccines could open up your holiday plans Simon Calder © Provided by The Independent The coronavirus pandemic is still extremely serious. Families are grieving: more than 108,000 people have died from Covid-19 in the UK. The virus spread rapidly across the world and into the UK by air travel. And the UK lockdown means holidays at home or abroad are currently illegal. But many people are looking ahead to later in 2021 and the opportunities for future holidays. With the UK well ahead of other major European nations in its vaccination programme to prote...

Press release content from Business Wire. The AP news staff was not involved in its creation. Indapta Therapeutics Announces Key Management Team Appointments to Advance into Clinical Trials in 2021 February 3, 2021 GMT SAN FRANCISCO--(BUSINESS WIRE)--Feb 3, 2021-- Indapta Therapeutics Inc. (“Indapta”), a biotechnology company focused on developing and commercializing a proprietary, first-in-class, off-the-shelf, non-engineered, allogeneic FcRγ-deficient natural killer (G-NK) cell therapy to treat multiple cancers, today announced the appointments of Lori Kunkel, M.D., as its Senior Clini...